edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: IRLAB Therapeutics
Edison Investment Research has terminated coverage on IRLAB Therapeutics (IRLAB-A). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
IRLAB Therapeutics — 7 videos in collection
IRLAB Therapeutics is a Sweden-based biotech company focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its integrative screening process technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD). PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.
In this interview, CEO Gunnar Olsson provides a recap of IRLAB’s ongoing central nervous system efforts and pipeline.
Get access to the very latest content matched to your personal investment style.